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Blood Cancer Research Group, Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland, UKAcute myeloid leukaemia (AML) is a heterogeneous clonal dis- in two cohorts (training; n = 266 and testing; n = 269) showed by
order arising in the myeloid lineage with an average age of around
62 years at diagnosis. Morphological and cytogenetic analysis has
identiﬁed a number of sub-types with a wide range of survival out-
comes. Some of the more favourable outcomes are associated with
patients who harbour balanced reciprocal chromosomal transloca-
tions including the t(15;17) translocation resulting in a fusion gene
between PML and RARα; this group of patients have acute
promyelocytic leukaemia (APL) (Freireich et al., 2014). Over the
past few years, next-generation sequencing has assisted in the
identiﬁcation of a spectrum of molecular mutations in many of
the other sub-types of AML, particularly in those with an apparent
normal karyotype.
Clinical trials have shown that patients with t(15;17) respond very
well to All-Trans-Retinoic-Acid (ATRA) or to ATRAwith arsenic trioxide
(ATO) resulting in some excellent outcomes inwhich there is an 85–90%
5-year overall survival (Coombs et al., 2015). ATRA has been widely
used in the treatment of APL due to its ability to speciﬁcally bind to
the ligand-binding domain of the RARα portion of the fusion protein,
resulting in the terminal differentiation and subsequent apoptosis of
the leukaemic promyelocytes. ATO which targets the PML portion has
been combined with conventional ATRA therapy resulting in degrada-
tion of the fusion protein. Furthermore, with this therapeutic combina-
tion, chemotherapy could be omitted for the patients who have low risk
APL (Coombs et al., 2015).
Unfortunately, evenwith the high rates of remission and overall sur-
vival, there remains a sub-set of APL patients who do not respond to
ATRA/ATO and it is these patients who highlight the need for better
stratiﬁcation upon diagnosis. An appropriate sub-division of patients’
needs to be applied at diagnosis, patients who would not respond to,
for example ATRA/ATO, could be treated with themost suitable therapy
based on their clinical and molecular presentation.
The study published in this edition by Shen et al. (2015) has
highlighted the need to stratify patients as they demonstrate a more
heterogeneous molecular picture associated with APL than previously
considered.
APL has been shown to require only the PML–RARα fusion pro-
tein, however Shen et al. (2015) in their study of 535 APL patientsDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.04.006.
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additional mutations typically associated with normal karyotype
AML patients in patients with APL. The most common mutations
were FLT3-ITD or -TKD (15.8%), WT1 (4.7%) and N-RAS (4.5%);
although the FLT3 mutation rate was lower than reported (43%) in
a previous study within the UK (Gale et al., 2005). However, if epige-
netic modiﬁer genes (EMGs) such as DNMT3A, TET2, IDH1, IDH2 and
ASXL1 were considered as a group, then 6.5% of APL patients had
EMG mutations. Overall, almost 1/3 of patients (30.6%) had a least
one mutation and the EMGs were often associated with other
mutations.
Furthermore, when the APL patients were stratiﬁed using Sanz's risk
scores (Sanz et al., 2000), over half (50.4%) of the high-risk patients
were more likely to harbour more than 2 mutations in addition to
PML–RARα. Of these, those with EMG mutations were associated with
a poorer outcome. Patients in the lower risk groups tended to have a
less complex mutational burden: 23.1% in low risk and 25.0% in the
intermediate groups. A similar landscape of mutated genes was seen
in each of the risk groups.
Shen et al. (2015) also showed a connection between mutational
burden and response to ATRA/ATO therapy: patients in the low-risk
groups responded to treatment better than those in the intermediate
and high-risk groups. However, the biggest discriminator for both over-
all survival and disease free survival, in the testing and training data
sets, was not FLT3 mutations but was the presence of mutations in the
EMG. This would point towards screening patients at diagnosis and
the development of a stratiﬁcation model encompassing the presence
of EMG mutations as a predictive indicator of resistance to treatment
with ATRA/ATO.
This study further conﬁrms that ATRA/ATO therapy is a highly
effective treatment for APL but clearly highlights the rationale for
alternative approaches targeting non-responding patients. Shen
et al. (2015) identiﬁed subsets of mutated genes contributing to a
previously unnoticed group of APL patients with poorer outcome
and provides the opportunity for the development of better targeted
therapies to treat high-risk disease. The inclusion of other mutations
outside of PML–RARα has opened up the possibility that APL should
be regarded as a more complex heterogeneous disease and ultimate-
ly may contribute to the improvement of the current stratiﬁcation
regimen currently employed in the clinic.
Future studies, in larger cohorts and in different centres, should ad-
dress the need to validate the use of other agents in combination withthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
488 C.S. Young et al. / EBioMedicine 2 (2015) 487–488ATRA/ATO such as epigeneticmodifying agents. This has been alluded to
in preclinical studies demonstrating the potential capacity for combina-
tion with HDAC inhibitors (De et al., 2014). However, a novel stratiﬁca-
tion model needs to be developed, at the point of diagnosis, to identify
those APL patients who are resilient to ATRA/ATO therapy.
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